Polyarteritis nodosa: PAN symptoms, organ assessment, hepatitis B and treatment

Polyarteritis nodosa (PAN) is inflammation of medium-sized arteries that can damage skin, nerves and internal organs by disrupting their blood supply. Confidence is high that suspected organ-threatening disease needs prompt specialist assessment. Treatment depends on whether disease is systemic, confined to skin, related to hepatitis B or part of a genetic PAN-like disorder. Disease overview. These forms should not share an automatic treatment recipe.

Table of contents

• Evidence summary
• What polyarteritis nodosa is
• How it works and how it is assessed
• The evidence-based treatments and their limits
• Supplement and lifestyle evidence
• What works and what is not established
• Risks, side effects and urgent warning signs
• Interactions and situations needing extra care
• Who needs assessment
• Clinician-led treatment and practical use
• Animal and in vitro evidence
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

The practical verdict is to establish the involved organs and the disease context before judging treatment. The 2021 ACR/VF original guideline addresses systemic, non-hepatitis-B PAN; its scope excludes cutaneous and hepatitis-B-associated disease. Most recommendations are conditional because evidence is limited. Guidance with author company ties is attributed rather than presented as an industry-free drug ranking.

No mortality percentage from an older cohort is used to predict an individual’s future. Disease classification and access to timely care have changed over time.

What polyarteritis nodosa is

PAN is a medium-vessel vasculitis. The NHLBI overview explains how inflamed vessel walls can become narrowed, blocked or weakened. Affected blood supply determines which tissues are harmed; “vasculitis” alone is not a complete diagnosis.

Systemic PAN can affect several organ systems; cutaneous PAN is a distinct skin-limited form. The Vasculitis Foundation guide describes skin lesions, nerve symptoms, abdominal involvement and high blood pressure among possible manifestations. A person need not have every symptom, and those symptoms have alternative causes.

PAN is distinct from the ANCA-associated vasculitides GPA, MPA and EGPA. A familiar acronym on a blood-test request does not decide which vessel disease is present. Ask the team which diagnosis the evidence supports and whether the label describes systemic disease, skin-limited disease or a related syndrome.

How it works and how it is assessed

Vessel inflammation can reduce organ perfusion and can produce weakened segments or aneurysms. Immune mechanisms and infections may be involved, but in many cases the initiating cause is unknown. NHLBI cause context. An infection-associated form is different from assuming that every case is caused by a recent infection.

Assessment combines history, organ examination, blood/urine tests and selected tissue or vessel studies. NHLBI diagnosis information. An elevated ESR or CRP is nonspecific; a result must be interpreted with the clinical pattern. A normal or improving number does not independently document the state of every artery.

The ACR/VF guideline describes targeted vascular imaging and biopsy. For a skin presentation, a sample must reach the relevant deeper vessels; for nerve symptoms, selected nerve/muscle assessment may be considered. These are clinical procedures, not a recommendation for every patient to have every possible biopsy.

Clarify what a scan or sample is intended to show, its limitations, and whether a result would change care. Previous treatment and the sampled site can affect interpretation. Keep actual reports available rather than relying on a remembered summary that a test was “positive.”

The evidence-based treatments and their limits

For severe systemic idiopathic PAN, the ACR/VF guidance describes glucocorticoids with cyclophosphamide; less severe disease can have other steroid-sparing strategies. The choice depends on organ threat, toxicity and the patient’s circumstances. No personalized dose, taper or automatic escalation rule is provided.

Hepatitis-B-associated PAN requires a distinct plan involving the infection as well as vascular inflammation. The French original recommendations describe specialist antiviral-based management and selected plasma exchange. This is not a universal instruction to suppress the immune system long term or to obtain a commercial plasma-exchange course.

Treatment has several goals: control active inflammation, protect blood supply, manage organ consequences and reduce medicine harms. NHLBI treatment context. Blood-pressure care, rehabilitation or a procedure can be needed for a separate consequence. Calling an intervention “supportive” does not make that consequence unimportant.

A medicine used for another vasculitis is not automatically established for PAN. Ask why it fits this diagnosis and severity, which evidence is direct rather than extrapolated, and what the team would do if the initial plan does not control disease.

Supplement and lifestyle evidence

No conflict-cleared human evidence identified in these sources shows that a supplement prevents PAN-related organ injury or replaces prescribed treatment. A deficiency, bone-health need or reduced food intake may warrant separate nutritional care, especially during a difficult treatment course.

The NCCIH safety guidance describes incomplete supplement evidence and interactions. Bring product names and ingredient lists rather than simply saying that a product is natural. Evidence about a laboratory inflammatory marker is not evidence of preventing arterial complications.

Activity and rehabilitation should account for nerve or muscle deficits, current pain and organ involvement. Practical goals can include safely managing daily tasks and preserving function. The care team should define the activity plan; forcing an impaired limb through a general exercise target is not a test of disease control.

General vascular care includes attention to prescribed blood-pressure treatment, smoking avoidance and follow-up. NHLBI living-with guidance. These measures do not prove remission of inflammatory disease and should be coordinated with, rather than substitute for, its treatment.

What works and what is not established

A useful follow-up distinguishes active disease from lasting damage and treatment toxicity. Persistent weakness may require neurologic or rehabilitation assessment even when inflammation is improving. Conversely, a new deficit should not be dismissed as an old scar without clinical review.

Optimal duration and several treatment comparisons remain uncertain in the original guideline. Older studies sometimes predated modern separation of PAN from other vasculitides. An apparent result from a historically mixed group does not automatically establish benefit in today’s narrowly defined PAN population.

Imaging should answer a particular question about activity, narrowing, an aneurysm or another complication. Repeated invasive tests during stable disease are not automatically beneficial. Ask which finding would alter treatment and how it will be compared with earlier results.

The French recommendations separate clinical activity from sequelae and treatment harms. Remission, recovery of nerve function and freedom from medication are different outcomes. A single improved symptom should not be translated into a promise that every consequence has resolved.

Risks, side effects and urgent warning signs

Seek emergency help for stroke symptoms, severe new chest/abdominal pain, collapse, major bleeding or a rapidly threatened limb. NHLBI complication context. In known PAN, an emergency may reflect the disease or another condition; neither should wait for a routine rheumatology appointment.

Report new weakness, foot/hand dysfunction, changing skin ulcers or significant blood-pressure problems promptly. The NHLBI organ-symptom information explains why the affected territory matters. Document when the change began; its timing can help distinguish a new process from a continuing problem.

Cyclophosphamide can suppress blood-cell production and cause important infection, bladder and reproductive risks. The Liverpool original safety leaflet advises prompt professional contact for fever, unexplained bleeding, urinary symptoms or unrelieved breathlessness. Its local monitoring schedule is not copied here as a universal regimen.

Glucocorticoids can affect bone, metabolism, infection risk and mood/sleep. NHS safety guidance. The team should review treatment harms alongside disease control; a side effect should not be ignored merely because the medicine serves an important purpose.

Interactions and situations needing extra care

Before immune-directed treatment, hepatitis status and infection risks need review. The French recommendations discuss hepatitis B reactivation under glucocorticoids or immunosuppression. Previous exposure and active infection are not identical; the relevant specialists decide monitoring and preventive treatment.

Review NSAIDs, aspirin and supplements if taking glucocorticoids. NHS prednisolone interaction guidance. Do not add a pain medicine without checking whether it creates risk alongside the existing plan, particularly with kidney or gastrointestinal involvement.

Methotrexate has important antibiotic and supplement interactions, including trimethoprim/co-trimoxazole. NHS interaction guidance. Medicines intended to prevent infection still require coordination with the exact immune-treatment regimen; the purpose of a medicine does not guarantee compatibility.

Discuss pregnancy, contraception and fertility preservation before treatment when feasible. Cyclophosphamide safety information. Urgent organ protection and reproductive planning need a coordinated decision, not a blanket instruction to delay every necessary treatment.

Who needs assessment

Unexplained systemic illness combined with skin lesions, nerve deficits, abdominal symptoms or blood-pressure changes warrants clinical assessment. A clinician must consider infections and other vascular or immune disorders as well as PAN. NHLBI assessment context. An online symptom match is not confirmation.

A childhood PAN-like illness, particularly with recurrent strokes or a suggestive family pattern, may prompt investigation for deficiency of adenosine deaminase 2 (DADA2). The French differential-diagnosis section identifies this distinct possibility. Genetic/functional testing and its treatment belong to a separate specialist assessment.

A skin-limited diagnosis needs follow-up if new symptoms suggest disease outside the skin. Cutaneous PAN and other skin vasculitides are not interchangeable labels. Bring photographs, prior biopsy reports and a list of changes, while allowing the clinician to decide the appropriate tests and urgency.

Clinician-led treatment and practical use

Ask the team to state the involved organs, treatment objective, required monitoring and emergency contacts. Keep the vascular, neurologic, renal and infection-related parts of the record together. A change of clinic should not erase the reason a medicine or procedure was chosen.

Prolonged prednisolone should not be stopped suddenly; tapering and symptoms during reduction require prescriber guidance. NHS stopping information. A planned taper can need reassessment if the disease, another illness or treatment tolerance changes.

Methotrexate for inflammatory disease is generally weekly, and a daily-dosing error needs urgent professional advice. NHS administration safety. Blood monitoring and prescribed folate support are parts of medication safety, not evidence that folate treats arterial inflammation.

Arrange rehabilitation and practical support where deficits affect walking, work or self-care. Ask how continuing nerve weakness will be assessed and what changes should trigger contact. A follow-up plan should address function and quality of life alongside blood results, without promising complete reversal of prior injury.

Animal and in vitro evidence

Laboratory and animal work can explore immune complexes, inflammatory pathways and vessel injury. The French original discussion notes that models do not fully explain non-hepatitis-B PAN. Mechanistic plausibility does not establish that a supplement or experimental immune intervention prevents human organ damage.

A proposed treatment needs relevant controlled human outcomes and safety data, with funding traced. Changes in a cell assay or an animal lesion are not interchangeable with remission, preserved nerve function or avoidance of arterial rupture. Such evidence is excluded from this guide’s treatment verdict.

Funding and source roles

Actual ACR/VF and French originals were read, including printed financial declarations. The French network has national ministry funding alongside mixed author company relationships and some Roche-supplied-drug underlying studies; those supplied-drug outcomes are Tier 4 and excluded from independent efficacy conclusions. ACR/VF professional/advocacy commercial routes and the Liverpool provider’s own public, private, research and donation income were checked. Government patient education is used for context rather than to clear all underlying trials. Sources are concentrated in US, French and UK clinical settings; no country is treated as a guarantee of reliability.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Is PAN an ANCA-associated vasculitis?
PAN is a distinct medium-vessel disease. GPA, MPA and EGPA belong to the ANCA-associated group; clinical assessment determines the relevant diagnosis.

Can a blood test confirm PAN?
No single blood test is sufficient. Clinical findings, exclusion of alternatives and appropriate imaging or biopsy matter.

Does hepatitis B change the plan?
Yes. HBV-associated PAN needs coordinated infection and vasculitis care; systemic non-HBV guidance cannot simply be copied.

Is skin-only PAN treated exactly like systemic PAN?
No. The systemic guideline excludes cutaneous PAN. Assessment must establish whether disease is confined to skin and whether that changes over time.

Should immune medicines continue forever?
Not automatically. Duration, remission, organ involvement, relapse and toxicity require specialist review; no personal stopping schedule is supplied.

Sources and funding notes

Full original 2021 ACR/VF PDF and 2020 French publisher text/financial declarations were checked. The latter’s 2021 correction concerns corresponding-author identity. No survival probability, specific scan interval or medication dose is copied. Medicines information is general safety context; NHS pages past their stated review dates are identified in their source roles. The separate Liverpool Trust leaflet has a May 2027 review date, and its own FY24/25 revenue notes were checked. ACR guidance excludes cutaneous/HBV PAN and relies substantially on sparse, dated or indirect evidence.

• ACR/VF: original 2021 PAN management guideline — Dated clinical framework; no cleared drug-effect percentages.
• Terrier et al.: original French recommendations, 2020/2021 correction — HBV-associated PAN distinctions, assessment and safety context; sponsored outcomes excluded.
• Vasculitis Foundation: PAN guide (February 2024) — Systemic/skin-limited distinction and symptom context; advocacy education, not cleared comparative outcomes.
• ACR: corporate support opportunities — Revenue model only.
• Vasculitis Foundation: audited FY 2024–25 accounts — Institutional funding model only.
• Vasculitis Foundation: awareness fundraising sponsors — Named commercial relationship only.
• NHLBI: vasculitis overview (May 2023) — Disease-family definition and vessel-size context; not cleared treatment trials.
• NHLBI: causes (May 2023) — Possible triggers and secondary causes; not an individual causal diagnosis.
• NHLBI: symptoms (May 2023) — Organ-specific manifestations and complications.
• NHLBI: diagnosis (May 2023) — Clinical, blood, urine, biopsy and imaging assessment; subtype-specific accuracy not assumed.
• NHLBI: treatment (May 2023) — Attributed general treatment context, not a comparative efficacy verdict.
• NHLBI: living with vasculitis (May 2023) — Follow-up, pregnancy planning and emergency complications; individual risks differ.
• NHLBI: budget and gift authority — Funding trace, not outcome evidence.
• NHS: prednisolone side effects — Infection, bone, metabolic and mood risks; medicine safety, not disease-specific efficacy.
• NHS: prednisolone use and stopping (February 2022) — Clinician-directed tapering and adrenal safety; stated review date has passed.
• NHS: prednisolone interactions (February 2022) — NSAID/aspirin and supplement cautions; dated general medicine context.
• NHS: methotrexate use (March 2023) — Weekly inflammatory-disease administration safety and monitoring; no personal dose.
• NHS: methotrexate interactions (March 2023) — Antibiotic, NSAID, supplement and vaccine review; stated review date has passed.
• NHS website: content and funding policy — Website funding and editorial safeguards only.
• NCCIH: using dietary supplements wisely — Safety and interaction limits, not proof of vasculitis efficacy.
• Liverpool University Hospitals: cyclophosphamide leaflet — Blood-count/bladder/infection/fertility safety; local instructions not a universal regimen.
• Liverpool University Hospitals: FY 2024/25 original accounts — Own provider funding route, not generic NHS branding.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.